Wang W, Cheng Z, Wang Y, et al
doi: 10.3892/mmr.2023.13114 18
Therapeutic Prospects BPC-157 is more stable than endogenous BPC and exhibits therapeutic properties without the need for a carrier agent
However, supraphysiological levels of GLP-1 (brought about by infusion) may increase glucose-stimulated insulin secretion to levels similar to those of control subjects receiving glucose alone [5]
You have three administration options: Option A: Injectable GHK-Cu only 200 to 600 mcg per day, subcutaneous Best for systemic tissue support (skin, joints, hair, internal tissues) No fasting required Option B: Topical GHK-Cu only Applied to target areas once or twice daily Best for localized skin concerns (face, abdomen, specific areas of laxity) Lower cost, no injection required Option C: Injectable plus topical (recommended for maximum benefit) Injectable for systemic support plus topical for targeted skin areas Most thorough approach Addresses both internal tissue health and external skin quality Step 4: Improve and Maintain As semaglutide is titrated up over the following months, continue GHK-Cu consistently
GLP-1 friendly dinner meals Dinner is where most people on GLP-1 medications face their biggest challenge